Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTSNASDAQ:CDXCNASDAQ:GHRSNASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTSJanone$9.73$6.20$1.29▼$10.40$169.84M2.14227,032 shs190,793 shsCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21798,821 shs554,788 shsGHRSGH Research$12.61+1.4%$10.35$6.00▼$20.50$656.07M0.97183,321 shs138,491 shsTRVITrevi Therapeutics$6.74+2.4%$6.24$2.30▼$7.48$673.28M0.591.31 million shs3.05 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTSJanone0.00%-1.62%+70.40%+89.67%+972,999,900.00%CDXCChromaDex0.00%0.00%0.00%+2.14%+175.00%GHRSGH Research+1.45%+4.39%+24.85%+20.10%+2.94%TRVITrevi Therapeutics+2.43%+5.97%+2.43%+56.74%+152.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTSJanoneN/AN/AN/AN/AN/AN/AN/AN/ACDXCChromaDex2.5492 of 5 stars3.50.00.04.00.60.01.9GHRSGH Research1.4874 of 5 stars3.50.00.00.01.92.50.0TRVITrevi Therapeutics3.5836 of 5 stars4.73.00.00.02.53.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTSJanone 0.00N/AN/AN/ACDXCChromaDex 3.00Buy$9.03∞ UpsideGHRSGH Research 3.00Buy$32.00153.77% UpsideTRVITrevi Therapeutics 3.30Buy$18.63176.34% UpsideCurrent Analyst Ratings BreakdownLatest ALTS, TRVI, CDXC, and GHRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.006/2/2025TRVITrevi TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.005/28/2025TRVITrevi TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$21.005/20/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.005/13/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025GHRSGH ResearchGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $29.005/9/2025GHRSGH ResearchHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/8/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.003/19/2025TRVITrevi TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $20.003/19/2025TRVITrevi TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.50 ➝ $12.503/19/2025TRVITrevi TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTSJanone$18.05M9.41N/AN/A($0.67) per share-14.52CDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00GHRSGH ResearchN/AN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTSJanone-$7.81MN/A0.00∞N/AN/A-2,940.01%-39.81%N/ACDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/AGHRSGH Research-$35.59M-$0.79N/AN/AN/AN/A-20.29%-19.49%N/ATRVITrevi Therapeutics-$29.07M-$0.45N/AN/AN/AN/A-63.31%-57.06%8/14/2025 (Estimated)Latest ALTS, TRVI, CDXC, and GHRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GHRSGH Research-$0.61-$0.19+$0.42-$0.19N/AN/A5/6/2025Q1 2025TRVITrevi Therapeutics-$0.13-$0.09+$0.04-$0.09N/AN/A3/18/2025Q4 2024TRVITrevi Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTSJanone$1.2212.54%N/AN/AN/ACDXCChromaDexN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTSJanone1.960.750.75CDXCChromaDexN/A2.952.35GHRSGH ResearchN/A15.8315.83TRVITrevi TherapeuticsN/A7.387.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTSJanone6.27%CDXCChromaDex15.41%GHRSGH Research56.90%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipALTSJanone4.90%CDXCChromaDex9.64%GHRSGH Research41.60%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTSJanone17017.46 million13.38 millionN/ACDXCChromaDex12077.75 million69.02 millionOptionableGHRSGH Research1052.03 million30.38 millionOptionableTRVITrevi Therapeutics2099.89 million58.13 millionOptionableALTS, TRVI, CDXC, and GHRS HeadlinesRecent News About These CompaniesTrevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesJune 5 at 4:30 PM | prnewswire.comAmeriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)June 5 at 3:14 AM | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Time to Buy?June 4 at 10:52 AM | marketbeat.comD. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)June 4 at 2:14 AM | americanbankingnews.comBrokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $18.63June 4 at 1:37 AM | americanbankingnews.comTrevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockJune 3 at 10:15 PM | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Stock Price Down 7.1% - Here's WhyJune 3 at 2:16 PM | marketbeat.comTrevi Therapeutics Announces Proposed Public Offering of Common StockJune 2, 2025 | prnewswire.comTrevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease PatientsJune 2, 2025 | benzinga.comTrevi Therapeutics (NASDAQ:TRVI) Reaches New 12-Month High - What's Next?June 2, 2025 | marketbeat.comTrevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral CapitalJune 2, 2025 | marketbeat.comTrevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 2, 2025 | prnewswire.comTrevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 1, 2025 | prnewswire.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by AnalystsJune 1, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for TRVI Q2 Earnings?June 1, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for TRVI Q2 EarningsMay 31, 2025 | marketbeat.comHC Wainwright Initiates Coverage on Trevi Therapeutics (NASDAQ:TRVI)May 30, 2025 | americanbankingnews.comH.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy RatingMay 29, 2025 | msn.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Still a Buy?May 29, 2025 | marketbeat.comHC Wainwright Begins Coverage on Trevi Therapeutics (NASDAQ:TRVI)May 29, 2025 | marketbeat.comTrevi Therapeutics to Participate in Upcoming June ConferencesMay 29, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALTS, TRVI, CDXC, and GHRS Company DescriptionsJanone NASDAQ:ALTS$9.73 0.00 (0.00%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$10.22 +0.48 (+4.98%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.ChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.GH Research NASDAQ:GHRS$12.61 +0.18 (+1.45%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$13.21 +0.60 (+4.73%) As of 08:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Trevi Therapeutics NASDAQ:TRVI$6.74 +0.16 (+2.43%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$6.78 +0.04 (+0.52%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
